MedTrace Logo

A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects

NCT06252961 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2024-09-20

No results posted yet for this study

Summary

The aim of the study is to evaluate the safety and efficacy of a 3- and 5-day course of levamisole (2.5 mg/kg) in management of loiasis microfilaremia.

Conditions

  • Loiasis

Interventions

DRUG

Levamisole 3 days

Levamisole for 3 days (2,5 mg/kg) then placebo for 2 days

DRUG

Levamisole 5 days

Levamisole for 5 days (2,5 mg/kg)

DRUG

Placebo

Placebo for 5 days

Sponsors & Collaborators

  • Institut de Recherche pour le Developpement

    collaborator OTHER_GOV

  • Programme National de Lutte contre l'Onchocercose, Republic of the Congo

    lead OTHER_GOV

Principal Investigators

  • Jéremy CAMPILLO, PharmD PhD · Institut de Recherche pour le Développement (IRD)

  • François MISSAMOU, MD · Programme National de Lutte contre l'Onchocercose (PNLO)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-21
Primary Completion
2024-09-18
Completion
2026-02-01

Countries

  • Republic of the Congo

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06252961 on ClinicalTrials.gov